Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy
2019 · Nature Communications · 79 citations
https://doi.org/10.1038/s41467-019-08541-2
H
Heidi M. Haikala
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
97
Papers
1.2K
Citations
11
h-index
13
i10-index
Heidi M. Haikala is an academic researcher from University of Helsinki. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Lung Cancer Treatments and Mutations & Renal cell carcinoma treatment. The author has an h-index of 11, co-authored 83 publications.
ORCID: 0000-0002-8465-8568Papers by this author
worksSortilin‐related receptor is a druggable therapeutic target in breast cancer
2021 · Molecular Oncology · 11 citations
https://doi.org/10.1002/1878-0261.13106
Shaping the battlefield: EGFR and KRAS tumor mutations’ role on the immune microenvironment and immunotherapy responses in lung cancer
2025 · Cancer and Metastasis Reviews · 9 citations
https://doi.org/10.1007/s10555-025-10272-4
Publisher Correction: Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy
2019 · Nature Communications · 1 citations
https://doi.org/10.1038/s41467-019-08956-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat